2026-01-20 - Analysis Report
**Comprehensive Analysis of AbbVie (ABBV)**

**Company Overview**: AbbVie is a biopharmaceutical company that develops and markets a range of medicines and vaccines.

**Return Rate Comparison**

* Cumulative return of ABBV: 175.47%
* Cumulative return of S&P 500 (VOO): 93.30%
* Divergence: 82.20 (max: 135.40, min: -20.20, relative divergence: 65.80%)

The cumulative return of ABBV is significantly higher than the S&P 500, indicating a strong investment performance.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019  | 42.0% | 21.6% | 24.0% | 1.1 | 156.5B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

**Recent Stock Price Fluctuations**

* Close: $214.35
* Last-market: $214.35 (-$0.31)
* 5-day SMA: $218.76
* 20-day SMA: $225.01
* 60-day SMA: $225.80

**RSI, PPO Index Indicators**

* Market Risk Indicator (MRI): 0.80 (Medium Investment)
* RSI: 34.11
* PPO: -0.56
* Hybrid Signal: Buy
* Recent (20 days) relative divergence change: -2.80 (worsening)
* 7-day Rank change: -2 (rank down)
* 7-day Dynamic Expected Return change: 4.00 (improving)

**Expected Return**: 40.20%

**Recent News & Significant Events**

1. Assessing AbbVie (ABBV) Valuation After Recent Share Price Pullback - Yahoo Finance UK
2. The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie - The Motley Fool
3. AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
4. AbbVie Call Options Spike 2,599%: Tracking the Big Bet - MarketBeat
5. AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs - TechStockÂ²
6. AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.04 / 289.00 / 184.00

**Comprehensive Analysis**: Based on the analysis of return rate, alpha, beta, stock price fluctuations, RSI, PPO index indicators, and recent news, AbbVie appears to be a strong investment opportunity with a high cumulative return, high alpha, and low beta. The company's stock price is currently fluctuating, but the overall trend is positive. The analyst consensus is also positive, with a buy recommendation and a target price of $245.04. However, it's essential to keep an eye on the company's epcoritamab trial and its potential impact on the stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.